

Application No. 09/760,810
Attorney's Docket No. 003300-737
Page 2

CLAIM SUMMARY DOCUMENT

Claim 1. (Currently Amended) A method of treating a nerve disorder mediated by nucleus pulposus in a mammal in need of such treatment wherein said nerve disorder mediated by nucleus pulposus is caused by the liberation of TNF- α and compounds triggered by the liberation of or presence of TNF- α comprising the step of administering a TNF- α inhibitor, wherein said TNF- α inhibitor is a metalloproteinase inhibitor excluding methylprednisolone for the treatment of nerve disorders mediated by nucleus pulposus in said to a mammal in need of such treatment wherein said nerve disorder mediated by nucleus pulposus is caused by the liberation of TNF- α and compounds triggered by the liberation of or presence of TNF- α by thereby inhibiting TNF- α and treating said disorder.

Claim 2. (Canceled)

E
8 Claim 3. (Previously Added) The method of claim 1, wherein said nerve disorder is a nerve root injury.

Claim 4. (Canceled)

15 Claim 5. (Currently Amended) The method of claim 3 1, wherein said nerve root injury is nerve disorder presents as sciatica.

2 Claim 6. (Previously Added) The method of claim 1, wherein the mammal is human.

9 Claim 7. (Previously Added) The method of claim 3, wherein the mammal is human.

Application No. 09/760,810
Attorney's Docket No. 003300-737
Page 3

Claim 8. (Canceled)

16 Claim 9. (Previously Added) The method of claim 8, wherein the mammal is human.

3 Claim 10. (Previously Added) The method of claim 1, wherein the TNF- α inhibitor is administered systemically.

10 Claim 11. (Previously Added) The method of claim 8, wherein the TNF- α inhibitor is administered systemically.

Claim 12. (Canceled)

17 Claim 13. (Previously Added) The method of claim 8, wherein the TNF- α inhibitor is administered systemically.

4 Claim 14. (Previously Added) The method of claim 1, wherein the TNF- α inhibitor is administered orally.

11 Claim 15. (Previously Added) The method of claim 8, wherein the TNF- α inhibitor is administered orally.

Claim 16. (Canceled)

18 Claim 17. (Previously Added) The method of claim 8, wherein the TNF- α inhibitor is administered orally.

Application No. 09/760,810
Attorney's Docket No. 003300-737
Page 4

5 Claim 18. (Previously Added) The method of claim 1, wherein the TNF- α inhibitor is administered intramuscularly.

8
12 Claim 19. (Previously Added) The method of claim 3, wherein the TNF- α inhibitor is administered intramuscularly.

Claim 20. (Canceled)

15
19 Claim 21. (Previously Added) The method of claim 5, wherein the TNF- α inhibitor is administered intramuscularly.

6 Claim 22. (Previously Added) The method of claim 1, wherein the TNF- α inhibitor is administered intravenously.

8
13 Claim 23. (Previously Added) The method of claim 5, wherein the TNF- α inhibitor is administered intravenously.

E
Cont
Claim 24. (Canceled)

15
20 Claim 25. (Previously Added) The method of claim 5, wherein the TNF- α inhibitor is administered intravenously.

Claims 26-48. (Canceled)

21 Claim 49. (New) The method of claim 1, wherein said nerve disorder is caused by a herniated disc.

Application No. 09/760,810
Attorney's Docket No. 003300-737
Page 5

21
~~20~~ Claim 50. (New) The method of claim 49, wherein the TNF- α inhibitor is administered intravenously.

21
~~23~~ Claim 51. (New) The method of claim 49, wherein the TNF- α inhibitor is administered systemically.

21
~~24~~ Claim 52. (New) The method of claim 49, wherein the TNF- α inhibitor is administered orally.

21
~~25~~ Claim 53. (New) The method of claim 49, wherein the mammal is human.

21
~~26~~ Claim 54. (New) The method of claim 49, wherein the TNF- α inhibitor is administered intramuscularly.

E
Cont
1 ~~27~~ Claim 55. (New) The method of claim 1, wherein said nerve disorder involves pain.

14 ~~28~~ Claim 56. (New) The method of claim 1, wherein said nerve disorder involves pain.

21
~~29~~ Claim 57. (New) The method of claim 49, wherein said nerve disorder involves pain.